Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical caffeine plus fluocinolone acetonide versus fluocinolone acetonide alone for chronic plaque psoriasis
IRCT20091012002581N10Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Nov 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in psoriasis comparing Caffeine 5% + fluocinolone acetonide 0.025% cream with Fluocinolone acetonide 0.025% cream (2 arms). Primary endpoint: Rate of recovery of lesions. Started Nov 2023; status: completed.
02
Drugs
caffeinefluocinolone
03
Conditions
psoriasis
Beyond the preview
Go deeper on IRCT20091012002581N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20091012002581N10.